Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Safety and Efficacy assessment of Monoprost (unpreserved latanoprost) in comparison with Lumigan 0.01 % and Lumigan 0.03% UD, in patients with open angle glaucoma or ocular hypertension, stabilized by Lumigan 0.01 % or Xalatan with ocular surface intolerance. Phase IV, international, multicentre, randomised, investigator masked, 3 months duration, 3 parallel groups, 3 X 120 evaluable patients

X
Trial Profile

Safety and Efficacy assessment of Monoprost (unpreserved latanoprost) in comparison with Lumigan 0.01 % and Lumigan 0.03% UD, in patients with open angle glaucoma or ocular hypertension, stabilized by Lumigan 0.01 % or Xalatan with ocular surface intolerance. Phase IV, international, multicentre, randomised, investigator masked, 3 months duration, 3 parallel groups, 3 X 120 evaluable patients

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 06 Apr 2020

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Latanoprost (Primary) ; Bimatoprost
  • Indications Glaucoma; Ocular hypertension
  • Focus Adverse reactions
  • Sponsors Laboratoires Thea
  • Most Recent Events

    • 18 Mar 2017 This trial has been completed in the United Kingdom (end date: 28 Jul 2016).
    • 28 Oct 2016 This trial was completed in Spain, according to European Clinical Trials Database.
    • 16 Mar 2016 Planned End Date changed from 1 Dec 2015 to 1 Jul 2016 as per ClinicalTrials.gov record.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top